Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-2690
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MK-2690 (also known as SPR2015) is an investigational, preclinical, orally administered molecular glue inhibitor targeting the active, GTP-bound 'ON' state of the KRAS G12D mutant oncoprotein. Originally developed by SciBrunch Therapeutics, the compound was licensed globally by Merck & Co. in September 2026. In preclinical studies, MK-2690 demonstrated nanomolar antiproliferative activity across various KRAS G12D-mutant cancer cell lines while maintaining selectivity over wild-type KRAS. It also showed robust monotherapy antitumor efficacy in cell-derived and patient-derived xenograft (CDX/PDX) models. The drug is being developed for the treatment of KRAS G12D-driven cancers, including pancreatic, colorectal, and lung cancers.
02
Targets
Beyond the preview
Go deeper on MK-2690.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-2690.